Extended Induction of Mirikizumab Sustains Efficacy and Safety Over 104 Weeks for Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Initial Induction

被引：0

作者：

D'Haens, Geert ^{[1
]}

Navabi, Seyedehsan ^{[2
]}

Chan-Diehl, Faye ^{[3
]}

Moses, Richard E. ^{[3
]}

Walter, James ^{[4
]}

Gibble, Theresa Hunter ^{[3
]}

Laharie, David ^{[5
]}

Gisbert, Javier P. ^{[6
]}

Vermeire, Severine ^{[7
]}

Kobayashi, Taku ^{[8
]}

Regueiro, Miguel ^{[9
]}

Johns, Jordan ^{[3
]}

Charabaty, Aline ^{[10
]}

机构：

[1] Univ Amsterdam, Med Ctr, Amsterdam, Noord Holland, Netherlands

[2] United Med Doctors, Long Beach, CA USA

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

[4] Einstein Healthcare Network, Philadelphia, PA USA

[5] Ctr Hosp Univ Bordeaux, Bordeaux, France

[6] Hosp Univ La Princesa, Madrid, Spain

[7] Univ Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium

[8] Kitasato Univ, Ctr Adv IBD Res & Treatment, Kitasato Inst Hosp, Tokyo, Japan

[9] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA

[10] Johns Hopkins Sch Med, Potomac, MD USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1139

引用

页码：S871 / S872

页数：2

共 50 条

[21] Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Reinisch, Walter
Sandborn, William J.
Hommes, Daniel W.
D'Haens, Geert R.
Hanauer, Stephen B.
Schreiber, Stefan
Panaccione, Remo
Fedorak, Richard N.
Tighe, Mary Beth
Huang, Bidan
Lazar, Andreas
GASTROENTEROLOGY, 2010, 138 (05) : S114 - S115
[22] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
J. Ignacio Fernández-Blanco
Guillermo Fernández-Díaz
Carlos Cara
María I. Vera
David Olivares
Carlos Taxonera
Digestive Diseases and Sciences, 2018, 63 : 731 - 737
[23] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Dubinsky, Marla C.
Betts, Keith
Eren, Devrim
Tang, Wenxi
Yin, Lei
Gupte-Singh, Komal
GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
[24] EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 2 TRIAL
Sandborn, William J.
Ferrante, Marc
Bhandari, Bal R.
Berliba, Elina
Hibi, Toshifumi
D'Haens, Geert R.
Tuttle, Jay
Krueger, Kathryn A.
Friedrich, Stuart
Durante, Michael
Arora, Vipin
Feagan, Brian G.
GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1094
[25] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Dubinsky, Marla
Lee, Scott D.
Panaccione, Remo
Abreu, Maria
Vermeire, Severine
Lissoos, Trevor
Morris, Nathan
Arora, Vipin
Dong, Yan
Naegeli, April
Sands, Bruce
INFLAMMATORY BOWEL DISEASES, 2020, 26 : S10 - S11
[26] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Dubinsky, Marla
Lee, Scott D.
Panaccione, Remo
Abreu, Maria
Vermeire, Severine
Lissoos, Trevor
Morris, Nathan
Arora, Vipin
Dong, Yan
Naegeli, April
Sands, Bruce
GASTROENTEROLOGY, 2020, 158 (03) : S17 - S18
[27] Corticosteroid-sparing effect of mirikizumab for the treatment of moderately-to-severely active Ulcerative Colitis: Extended induction subgroup analysis from Phase 3 trial
Laharie, D.
Siegel, C.
Dulai, P.
Matsuoka, K.
Gisbert, J.
Samaan, K.
Redondo, I.
Baygani, S.
Paulissen, J.
Jairath, V.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1687 - I1688
[28] The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
Shin, S. Shin
Park, S. J.
Kim, Y.
Im, J. P.
Kim, H. J.
Lee, K. M.
Kim, J. W.
Jung, S. A.
Lee, J.
Kang, S. B.
Shin, S. J.
Kim, E. S.
Kim, Y. S.
Kim, T. O.
Kim, H. S.
Park, D. I.
Kim, H. K.
Kim, E. S.
Kim, Y. H.
Kim, D. H.
Teng, D.
Kim, J. H.
Kim, W. Y.
Choi, C. H.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S432 - S432
[29] Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
Kobayashi, Taku
Matsuoka, Katsuyoshi
Watanabe, Mamoru
Hisamatsu, Tadakazu
Hirai, Fumihito
Milata, Joe
Li, Xingyuan
Morris, Nathan
Arora, Vipin
Ishizuka, Tomoko
Matsuo, Koji
Satoi, Yoichi
Milch, Catherine
Hibi, Toshifumi
INTESTINAL RESEARCH, 2024, 22 (02) : 172 - 185
[30] Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis
Sandborn, William J.
Peyrin-Biroulet, Laurent
Quirk, Daniel
Wang, Wenjin
Nduaka, Chudy, I
Mukherjee, Arnab
Su, Chinyu
Sands, Bruce E.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (08) : 1821 - +

← 1 2 3 4 5 →